Literature DB >> 22391257

Statins personalized.

H Robert Superko1, Kathryn M Momary, Yonghong Li.   

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor medications, commonly referred to as statins, are among the most widely prescribed medications. Variation in individual response to statins concerning low-density lipoprotein cholesterol reduction, clinical event benefit, and side effects has been observed. Some of this variability is attributed to demographic and environmental issues, chief of which is compliance. A large portion of the individual response to statin therapy is attributed to single nucleotide polymorphisms that have recently been elucidated, several of which seem to have clinical utility. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391257     DOI: 10.1016/j.mcna.2011.11.004

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  16 in total

Review 1.  Genetics and personalized medicine--a role in statin therapy?

Authors:  Jaideep Patel; Thura Abd; Roger S Blumenthal; Khurram Nasir; H Robert Superko
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  Feasibility study for removing calcified material using a planar rectangular ultrasound transducer.

Authors:  Christakis Damianou; Andreas Couppis
Journal:  J Ultrasound       Date:  2016-01-12

4.  Deciphering Genome Environment Wide Interactions Using Exposed Subjects Only.

Authors:  Lue Ping Zhao; Wenhong Fan; Gary Goodman; Jerry Radich; Paul Martin
Journal:  Genet Epidemiol       Date:  2015-02-18       Impact factor: 2.135

5.  Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.

Authors:  Georgia Ragia; Vana Kolovou; Anna Tavridou; Laure Elens; Alexandros D Tselepis; Moses Elisaf; Ron H N Van Schaik; Genovefa Kolovou; Vangelis G Manolopoulos
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

6.  Statin use in Australian children: a retrospective audit of four pediatric hospitals.

Authors:  Ingrid C Gelissen; Huy Long Nguyen; Darren K Tiao; Rita Ayoub; Parisa Aslani; Rebekah Moles
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

Review 7.  Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.

Authors:  Michael J Sorich; Michael D Wiese; Rebekah L O'Shea; Brita Pekarsky
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 8.  CYP51 as drug targets for fungi and protozoan parasites: past, present and future.

Authors:  Galina I Lepesheva; Laura Friggeri; Michael R Waterman
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

9.  No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.

Authors:  E Giannakopoulou; G Ragia; V Kolovou; A Tavridou; A D Tselepis; M Elisaf; G Kolovou; V G Manolopoulos
Journal:  Mol Biol Rep       Date:  2014-03-26       Impact factor: 2.316

10.  Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design.

Authors:  Tatiana Y Hargrove; Laura Friggeri; Zdzislaw Wawrzak; Suneethi Sivakumaran; Eugenia M Yazlovitskaya; Scott W Hiebert; F Peter Guengerich; Michael R Waterman; Galina I Lepesheva
Journal:  J Lipid Res       Date:  2016-06-16       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.